GPCR

Structure Therapeutics is a clinical-stage biopharma with zero product revenue and widening losses (-$141M in FY2025 vs -$123M in FY2024, per the 10-K's own recap of '$141.2 million, $122.5 million and $89.6 million'). The investment case is entirely about the pipeline: aleniglipron (GSBR-1290), an oral small-molecule GLP-1R agonist 'currently in five ongoing clinical studies for the treatment of obesity,' plus two amylin candidates (ACCG-2671 in Phase 1 and ACCG-3535) and preclinical GIP/glucagon programs. The MD&A explicitly frames oral small molecules as 'potentially differentiated efficacy and safety and... more scalable to meet global demand' versus injectable peptides — the bull case in one line, if the data lands.

The balance sheet is the reason this is a hold rather than an avoid. Cash and equivalents jumped 371.7% YoY to $800M, total assets grew 75.3% to $1.58B, and liabilities/equity sits at a trivial 0.04x. That is fresh capital — almost certainly a raise, given shares outstanding grew 23.5% to 213M — and it funds the burn for a while: operating cash flow was -$222M in FY2025 (worsened 90.5%), and R&D doubled (+107%) to $225M as trials scale. At current burn the company has roughly 3–4 years of runway before another dilutive raise, which is unusually comfortable for a Phase 2 biotech.